PresentationPresentation Phase 2 Results of Selinexor in Advanced De- Differentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study PDF (960.41 KB) Read MorePresentation Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML PDF (1.02 MB) Read MorePresentation Selinexor in Combination with Weekly Low – Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma PDF (1.09 MB) Read MorePresentation Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone (SPd) in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure PDF (1.01 MB) Read MorePresentation A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab (SDd) in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs PDF (992.29 KB) Read MorePresentation Eltanexor (KPT-8602), a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma PDF (2.26 MB) Read MorePresentation Phase I/II Trial of the Combination of Selinexor (SEL), Liposomal Doxorubicin (DOX) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma PDF (1.28 MB) Read MorePresentation Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) PDF (387.18 KB) Read MorePresentation A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone (SRd) in Patients with Relapsed / Refractory Multiple Myeloma PDF (1,000.31 KB) Read MorePresentation A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3- mutated Acute Myeloid Leukemia (AML) PDF (590.56 KB) Read More Previous 1 2 3 4 … 15 Next